HGS in search for cancer, immunology drugs acquisitions
Rockville-based Human Genome Sciences (HGS), a maker of the experimental lupus medicine Benlysta, is seeking partnerships and acquisitions in cancer and immune-system disorders.
HGS is set to start selling Benlysta along with its partner, London-based GlaxoSmithKline, if the USFDA clears the medicine by 10 March, reported Bloomberg.com.
Benlysta prevents the production of antibodies that attack healthy cells, causing swelling, joint and muscle pain, rashes and fever.
With the USFDA's approval, it would become the first approved drug for lupus in more than 50 years, HGS said.
Bloomberg.com has quoted CEO Tom Watkins as saying that the company would be interested in any specialty market where there is a significant unmet medical need, particularly where a large molecule could be a player.
"Benlysta will continue to be the growth vehicle for the next few years, but HGS would ensure a big pipeline to be sustainable as a growth company," Watkins said.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $0